Strategic Analysis: Roche's Forced Decision on Arrowhead Pharmaceuticals Acquisition
Part Three of Three Roche: The Disciplined Pioneer Forced to Move
Read the full articleYou might also wanna read
Enterprise AI Profile: The Roche Group
The Roche Group and its subsidiaries are using AI to advance pharmaceutical R&D and healthcare diagnostics and treatment
Futuriom·10mo ago
China's biotech rise: A case study in multiple myeloma drug development
A drug for multiple myeloma should have been an early warning that China is racing ahead in biotech
writingruxandrabio.com·17d ago
How AI Will Transform Biopharma: The Sequence of Change Matters
How AI will transform biopharma—and why the sequence of change matters
a16z.news·18d ago
Carlyle faces regulatory divestiture demands in BASF deal; Incyte acquires Vega Therapeutics
Here’s what we’re watching in the chemical and pharmaceutical industries this week
cen.acs.org·28d ago
Enabling Widespread Adoption of Transformative Biopharmaceutical Technologies: Insights from Roundtable 1 of the 2025 BioInnovation Group Executive Summit
Summarizing insights from the first of six roundtable discussions at the September 2025 BioInnovation Group (BIG) Executive Summit, this art
bioprocessintl.com·1mo ago
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry pa
Bars·5d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.